

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

Sensipar (cinacalcet)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Sensipar (cinacalcet)	May be subject to quantity limits

APPROVAL CRITERIA

Request for Sensipar (cinacalcet) may be approved for individuals who meet the following criteria:

- I. Individual has been on Sensipar (cinacalcet) in the past 180 days (medication samples/ coupons/ discount cards are excluded from consideration as a trial); **OR**
- II. Individual is 18 years of age or older; **AND**
- III. Individual has a diagnosis of secondary hyperparathyroidism (HPT); **AND**
- IV. Individual is currently on dialysis for chronic kidney disease (CKD); **AND**
- V. Individual has a serum corrected total calcium greater than 8.4 mg/dl; **AND**
- VI. Individual has a serum intact plasma parathyroid hormone (iPTH) level greater than 150 pg/ml; **AND**
- VII. Individual has had an inadequate response or intolerance to treatment with oral phosphate binders or oral generic vitamin D analogs; **OR**
- VIII. Individual is 18 years of age or older; **AND**
- IX. Individual has a diagnosis of parathyroid carcinoma with hypercalcemia; **AND**
- X. Individual has a serum corrected total calcium greater than or equal to 10.2 mg/dL (NKF 2003); **OR**
- XI. Individual is 18 years of age or older; **AND**
- XII. Individual has a diagnosis of primary HPT with severe hypercalcemia; **AND**
- XIII. Individual is unable to undergo parathyroidectomy; **AND**
- XIV. Individual has a serum corrected total calcium greater than 12.5 mg/dL; **OR**
- XV. Individual is 18 years of age or older; **AND**
- XVI. Individual is a renal transplant recipient with a diagnosis of persistent hyperparathyroid-associated hypercalcemia (DrugPoints B IIa); **AND**
- XVII. Individual has a serum corrected total calcium greater than 10.5 mg/dL (Evenepowl et al. 2014).

Sensipar (cinacalcet) may not be approved for the following:

- I. Individual has a diagnosis of secondary hyperparathyroidism with chronic kidney disease and is not on dialysis.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.